The range includes:
Fluodrop (the first fluorescein product specifically designed for veterinary use)
Ocryl - an ocular and periocular cleanser that can also be used to reduce and prevent unsightly tear staining
Ocular lubricants (carbomer and hyaluronic acid based)
Clerapliq – a novel molecule to the UK veterinary market that is used to help restore and regenerate the corneal extracellular matrix
The products will be supported with a selection of materials to help vets, nurses and pet owners in the maintenance of corneal health, including diagnosis and treatment guidelines, anatomical guides, posters and client educational and treatment aids to help with compliance.
William Peel MRCVS, product manager at TVM-UK said: "Our Corneal Focus Range is an exciting way to expand on our product portfolio following the successful introduction of our ‘Anti-tox’ range.
"With ‘Anti-tox’ we successfully managed to make vets and nurses lives easier by providing education and materials alongside a great range of products to help when dealing with poisoning cases in practice. We also attempted to make clients more aware of the dangers of poisoning in pets.
"We hope to emulate this approach and success with our Corneal Focus Range – by developing a wealth of materials for vets, nurses and clients to aid them in managing and understanding ophthalmology cases – and by providing quality products."
TVM UK will be showcasing its new products and support services at the London Vet Show (stand P40) this November.
For more information, visit: http://www.tvm-uk.com/
The researchers, from the Dick Vet Equine Hospital, University of Edinburgh, Newcastle University, Istituto Zooprofilattico Sperimentale delle Venezie, and the University of Padova found that affected horses have major abnormalities in the structure of their neuromuscular junctions, microscopic sites of communication between nerves and muscles that are crucial for normal muscle function.
These abnormalities are believed to represent a toxin specific signature, effectively a ‘smoking gun’, for a neurotoxic enzyme termed a phospholipase A2.
Work is now underway to definitively identify the source of the toxin, in the hope that it will lead to novel treatments and improved diagnostics for this devastating disease.
The researchers think the toxin is likely to be produced by a microbe such as a bacterium or fungus growing on the horse’s pasture during the cold and dry weather which commonly precedes the disease.
Neurotoxic phospholipase A2 toxins are also present in the venom of many poisonous snakes, and there are many similarities between the signs of grass sickness and those of snake envenomation.
While there is no suggestion that venomous snakes cause grass sickness, it is hoped that some of the drugs that are currently being developed to treat and promote nerve regeneration in people paralysed by snake venoms can aid recovery of horses from grass sickness.
The researchers say that the neurotoxin most likely also causes the apparently identical diseases (termed animal dysautonomias) which affect cats, dogs, hares, rabbits, llamas, alpacas and sheep, and that their finding contradicts the previous leading hypothesis that grass sickness is a form of botulism.
This breakthrough is summarised in an editorial in the January 2025 issue of the Equine Veterinary Journal (EVJ).
The editorial, by Bruce McGorum and colleagues, looks at the implications of their article 'Equine grass sickness is associated with major abnormalities in the ultrastructure of skeletal neuromuscular junctions2".
Bruce said: “Identifying a probable cause of Equine Grass Sickness represents a significant breakthrough.
"We hope that this discovery will lead to novel treatments and improved diagnostics for this devastating condition.
"We are very grateful for the generous support we have received from horse owners, veterinary surgeons, scientists, charities and funding bodies.”
Bruce's editorial is currently available on Early View, free for 12 weeks, and will also be published in the January 2025 print issue of the EVJ.
Reference
The session will be conducted in the style of the BBC Radio 4 Moral Maze discussion programme, with panelists and witnesses arguing for and against the viewpoint corporatisation is inevitable and will benefit vets and their clients.
Moderated by Madeleine Campbell, Keith Chandler and Karl Holliman will argue for corporatisation and Andrew Harrison and Tim Greet will be against. They will call upon a series of 'witnesses' for detailed questioning before the topic is more broadly debated.
CVS, the UK’s biggest veterinary group now owns more than 410 veterinary practices, of which over 30 are specifically equine or mixed practices.
The latest equine acquisitions include Bell Equine, a one-site Equine Referral Hospital in Kent, in January 2017 and Severn Edge Veterinary Group, a mixed practice with 12 sites in Shropshire, including a six-vet dedicated equine practice, in April 2017.
One line of argument says that the commercial and business advantages of a corporate, together with their scale and diversity, can give veterinary surgeons greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
On the flip side, there's the removal of any opportunity to buy into ownership, reduced decision-making ability because of adherence to corporate procedures, extra paperwork, longer approval processes and an increased emphasis on the bottom line.
David Mountford, Chief Executive of BEVA said: "The auditorium is usually full to bursting for our Moral Maze sessions because they bring a broader and more engaging dimension to important topics. The statement Corporatisation of equine practices is inevitable and will benefit vets and their clients is bound to generate some stimulating and possibly heated debate."
This year's BEVA Congress will be held at Liverpool Arena Convention Centre, and anyone who registers before 3rd August will receive significantly reduced booking fees.
For more information, visit: www.beva.org.uk.
If you’re a show-jumping vet, you might like to take part in the first-ever international veterinary-only riders competition – held in the beautiful region of Lure at the foot of the Vosges in France.
The French association of veterinary riders (AFVC) invites all veterinary riders to contend for the First World Veterinary Equestrian Show Jumping Cup, to be held from July 3 to 6, 2008.
The event is open to all qualified veterinarians and veterinary students, who may participate with or without their own horse.
The event will include four show-jumping competitions (one per day), while the social programme consists of a Gala evening (Friday), a dinner-dance (Saturday, sponsored by Merial) and a Sunday lunch (major sponsor of the event: Equistro / Vétoquinol).
The veterinary show-jumping event will coincide with France’s 6th Grand National show-jumping competition, also held in Lure.
For further information, please contact: David Smart DVM, david.smart@vetoquinol.com or your local Vétoquinol representative.
Boehringer Ingelheim Vetmedica has launched Buscopan 20mg/ml injection, an antispasmodic treatment for use in cases of equine colic, and an aid to the symptomatic treatment of calf scour.
A sister product to Buscopan Compositum which contains both an antispasmodic and a non-steroidal component, Buscopan 20 contains only the antispasmodic component - hyoscine butylbromide.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Our customers have been telling us for some time that they would really welcome a Buscopan formulation without an NSAID for use in horses and cattle. I'm pleased to say that it's finally here and I'm sure that Buscopan 20 will be a very welcome addition to the armoury of both equine and cattle practitioners."
Buscopan 20 is supplied in a 50ml multi-dose bottle, and is available in veterinary wholesalers now.
For further information, please call 01344 746959.
The survey is open to all veterinary surgeon members and participants will be entered into a free prize draw to win £500 of BEVA CPD vouchers.
As we all know, antibiotic resistance is increasing throughout human and veterinary medicine, and there are few new antibiotics being produced. As BEVA says, it’s therefore imperative for vets to protect the usage of antimicrobials to maintain their effectiveness for the future.
To that end, the purpose of the survey is to help fill in gaps in knowledge about how antimicrobials are being used and also the current landscape of resistant infections encountered in equine practice.
The survey has been designed by Amie Wilson and Dr Gina Pinchbeck at the University of Liverpool and Tim Mair the incoming President of BEVA.
Tim said: "This survey will assess any changes in prescribing of antimicrobials in equine practice since the last survey in 2009. In addition, we will collect data on the current frequency and types of antimicrobial resistant infections seen by clinicians in all areas of equine practice and what infection control and audit practices are currently using to combat this."
The survey results should lead to a greater understanding of the role of antimicrobial treatment in the overall epidemiology of antimicrobial resistance in horses and will help protect antibiotics for the future of equine and human health.
To take part in the survey, visit: https://liverpool.onlinesurveys.ac.uk/beva-questionnaire-2019-final
The results will be announced to coincide with European Antibiotic Awareness Day on 18 November 2019.
If you have any questions about the survey you can contact the researchers direct: Amie Wilson, University of Liverpool A.wilson3@liv.ac.uk; Dr Gina Pinchbeck, University of Liverpool ginap@liv.ac.uk; Tim Mair, British Equine Veterinary Association tim.mair@btinternet.com
Dr Neil Bryant from the AHT, who is leading the research, said: "EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world. It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease."
As a viral infection, EHV can cause respiratory disease, abortion or fatal illness in new born foals and neurological disease in adult horses, with signs ranging from slight wobbliness through to complete paralysis. The disease can strike any horse at any time because the virus, like other herpesviruses (such as the cold sore virus in humans), becomes dormant within most horses early in their life. It then re-emerges when the animal is later stressed such as when transported or mixed with new horses. A seemingly healthy pregnant mare may suddenly, and without warning, abort her unborn foal or may show signs of respiratory disease including mild fever, coughing and discharge from the nose. A horse which appears fit and well may suddenly show abnormalities when walking and within hours may be unable to stand.
Despite the potential severity and impact of outbreaks, there is still no vaccine that is licensed to protect against the neurological form of the disease and abortions still occur in highly vaccinated horse populations. The AHT says protection afforded by existing vaccines currently in use is sub-optimal, something that was highlighted by the 2016 abortion storm in Hertfordshire in fully vaccinated animals.
Neil added: "We have become aware of a pressing need for progress towards a new and improved EHV-1 vaccine. Just last month, the AHT was again called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in premises in Yorkshire and Suffolk."
To that end, the charity has now established the Equine Industries EHV Vaccine Steering Group. Chaired by Professor Joe Brownlie of the RVC, the steering group includes world-renowned experts on both human and equine herpes viruses from a number of research establishments, who have concluded that the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.
After securing funding from a large number of organisations, including the Alborada Trust, EBM Charitable Trust, Horserace Betting Levy Board and the Racing Foundation, Paul Mellon Estate, Thompson Family Charitable Trust, Coolmore Ireland, Newsells Park Stud, Thoroughbred Breeders’ Association and Juddmonte Farms, the AHT has begun its five-year research programme.
Neil added: "We’re at the beginning of a very exciting and potentially ground-breaking vaccine development. Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs. We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1."
The survey will assess vets’ experiences of the disease, biosecurity and the role of vaccination to help prevent strangles.
It includes questions on the number of strangles cases diagnosed in the last year, how the diagnosis was reached and in what instances they would recommend strangles vaccination.
The survey, which is approximately two minutes long, is at: https://forms.office.com/e/wH1UeVFmVW.
All participants will be entered into a prize draw for a £50 Amazon voucher.
For further information on Strangles Awareness Week: https://www.redwings.org.uk/strangles/strangles-awareness-week.
BlueSky says that conventional treatment for equine sarcoids, which are induced by tumour antigens E6 and E7 of the bovine papillomavirus, have only limited effect and typically result in the recurrence of the tumours.
However, research published by the company in PLoSONE1 showed that sarcoids treated with delNS/E6E7 were completely and permanently eliminated.
For the study, 29 horses were treated with different regimes involving direct injection into the tumours over three years.
Visible and very significant regression of the sarcoids was achieved in 20 of the treated horses, and 100% regression of the sarcoids in 10 equine patients.
Thomas Muster, CEO of BlueSky Immunotherapies said: "The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform."
In addition, the systemic delNS-mediated immune stimulation eliminated non-injected sarcoids and the papillomavirus that caused the sarcoids.
Thomas added: "We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently under way."
This year the event delivered more than 90 hours of CPD lectures, workshops and practicals across six separate streams, over three days. Over 100 veterinary industry leaders showcased their wares in the commercial exhibition hall and there were a number of social events for delegates.
Delegates awarded the scientific programme an average score of 4.7 out of 5 stars, and 94% of delegates said they will put what they learnt into practice and use it in their day-to-day role. 94% also said Congress was good value for money.
Swissvet, a company which makes power dentistry equipment, won the Veterinary Practice Best New Exhibitor Award. CEO Dr Ruedi Steiger said: We have distributors throughout Europe, but it is the first time Swissvet has exhibited at BEVA. It has been a fantastic experience and I am thrilled to have won this award. I definitely plan to come back next year."
Next year’s BEVA Congress will be held in Birmingham from 9-12 September 2020. For further information visit www.beva.org.uk.
Photo: David Boughey
Petplan Equine is now seeking nominations for the Equine Vet of the Year Award 2009, an award to recognise vets that go above and beyond with their care of horses and their owners.
Andrew Dobson of The Barn Equine and Large Animal Practice in Great Wakering, Essex, is the current 2008 Equine of the Year. He was nominated by a number of his grateful clients and their glowing testimonials impressed the judges enough to give him the edge over his closest rivals for the title.
The 37 year old qualified in 1999 and for the last four and a half years has run his own practice. His involvement with horses evolved from a desire to work with large animals and the outdoor life it would bring.
Andrew said: "I was absolutely stunned. I'm so honoured and amazed to have received the Petplan Equine Vet of the Year award. I really enjoy what I do and would like thank all my clients, Petplan Equine and The Animal Health Trust for their support."
If you feel you know a vet that displays equine clinical excellence and fantastic customer care you can nominate online by visiting www.petplanequine.co.uk/events Nominations close 3rd October 2009. An independent panel will judge the nominations and the winning vet will be announced at the Animal Health Trust UK Equestrian Awards in London, in November 2009.
Pat is the head of the Equine Studies Group at Waltham Petcare Science Institute and an internationally renowned authority on equine nutrition from both veterinary and academic perspective.
Her courses, book publications and webinars are aimed at providing practising equine vets with the latest knowledge and essential know-how on equine nutrition, whether for performance horses, leisure animals or the retired family pony.
Earlier this month Pat was one of several speakers at the British Equine Veterinary Association’s CPD course: From superfoods to supplements: How to know more than the owner.
Earlier this year she co-edited and co-authored two chapters of Veterinary Clinics Equine Practice: Nutrition: 1) What would be good for all veterinarians to know about equine nutrition, and 2) Nutritional considerations when dealing with an obese adult equine.
Next month she will chair a panel discussion titled Nutritional Management of the Competitive Equine Athlete for Vets through VetPD.
In the autumn she will be one of several speakers at the Mars Equestrian Equine Veterinary Continuing Education Series focusing on senior, obese and laminitic horses.
For more information, visit: www.spillers-feeds.com
The charity says that it had already been suffering a period of 'dire financial constraints' and the economic effects of coronavirus are now having a direct effect on funding.
The charity's Trustees and Executive Committee is still trying to find emergency funding to try and save the organisation, failing which it will close on the 31st March.
Equip EHV 1,4 is licensed for the active immunisation of horses to reduce clinical signs due to infection with Equine Herpesvirus 1 and 4 and to reduce abortion caused by EHV-1 infection.
Zoetis says it has already communicated directly with veterinary surgeons to inform them that Equip Rotavirus will be out of stock from the end of November 2017 until mid-2018.
During this time an imported vaccine for Rotavirus, will be available to provide an interim solution until supply is restored.
Practices wanting to buy the alternative imported Rotavirus vaccine will need to apply to the VMD for a Special Treatment Certificate (STC).
The company says it acknowledges the concern and frustration this causes its customers and wants to reassure the equine community that it is working diligently to restore the supply of Equip Rotavirus as soon as possible.
For more information, contact your Zoetis account manager or Zoetis technical team.
Zoetis has announced the introduction of Equimidine solution in a 50% larger plastic bottle.
The company says the new 15ml multi-dose presentation, now in plastic rather than glass, offers greater safety, as well as cost-saving advantages to practices.
Equimidine, containing 10mg/ml detomidine hydrochloride and methyl parahydroxybenzoate 1 mg/ml as a preservative, is a clear solution for intravenous injection. It has sedative and analgesic properties and is indicated for use either alone or in combination with butorphanol to facilitate the handling of horses for clinical examinations, minor surgical procedures and other manipulations. It can also be used with ketamine for short duration general anaesthesia for surgical procedures such as castration.
According to the company, the new 15ml plastic bottle is more cost-effective per dose than the old 10ml glass vial. It is also safer to use as the bottle is less likely to break if accidentally dropped. The multi-dose facility involves a tightly fitted rubber bung through which a sterile needle can be inserted to withdraw each dose.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "The new presentation provides practical benefits for vets and the larger bottle size means the product is now even more cost-effective."
For more information, speak to your Zoetis Account Manager, refer to the SPC or contact Zoetis Customer Support on 0845 3008034.
Kruuse has launched a range of seven specialized sterile surgical disposable drapes and gowns developed for the surgery team working in equine clinics or hospitals.
The company says its new surgical sets have been designed so they include a comprehensive set of sterile drapes, towels, instrument covers and adhesive tapes needed to perform particular procedures:
Andrew Groom, Managing Director, Kruuse UK Ltd. said: "This exciting new range of products increase the Kruuse's equine product portfolio and develop further our commitment to provide specialist species available products to support the veterinary practitioner."
Woodley Equipment Company has announced that Veterinary Parasep Faecal Filters are now available exclusively from the company.
According to the Woodley, the filters have been developed in conjunction with an independent leading veterinary Institution and offer an improved method of determining Worm Egg Counts (WEC) on cattle, sheep and horses. Flotation methods for WEC can require several Specific Gravity solutions to cover different parasites. The two common flotation methods, ‘Modified McMaster' and ‘Improved Modified McMaster', both use Saturated NaCL and are both catered for with Veterinary Parasep.
Woodley says the key advantages of the new filters are:
For a more information about The Veterinary Parasep please email sales@woodleyequipment.com or call the customer service team on +44 (0) 1204 669033 ~ Option 1.
Alternatively, visit http://www.woodleyequipment.com/.
The company says it is launching the new slCT after achieving success imaging horses in collaboration with its UK-based clinical trial sites.
The new standing CT scanner has a unique low, flat platform for quick and easy entry and exit of the standing sedated horse.
The system uses a dual-concentric ring design which enables the detector plate to remain very close to the region of interest, thereby improving image quality.
Hallmarq says slCT is a good fit for equine practices wanting to step up to 3D imaging in the evaluation of their lameness cases.
Bell Equine in Kent, Sussex Equine in Ashington, and Berkshire- based Donnington Grove Equine were involved in early trials of novel system.
Dr Elisabetta Giorio from Donnington Grove says slCT complements their sMRI which highlights soft tissue and metabolic changes: “The combination of MRI and CT was a useful tool to have and helped with surgical planning and decision making".
For more information, visit: https://hallmarq.net/
Dr Wendy Talbot BVSc DipECEIM MRCVS, Equine National Veterinary Manager at Zoetis said: “Fast equine faecal egg count results are crucial for the appropriate and timely treatment of gastrointestinal parasites, and to detect the increasingly concerning issue of dewormer resistance in horses.
"This technology is proven to be as accurate at identifying Strongyle spp. and Parascaris spp. as a board-certified parasitologist, delivering fast, reliable and shareable results within 10 minutes.1”
Zoetis says study results have demonstrated the AI capability within the Vetscan Imagyst to be up to 99% in agreement with board-certified parasitologist results1.
This, says the company, allows for rapid identification of high shedders versus low shedders to enable strategic targeted deworming protocols to be implemented.
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
The vaccine will be available to order directly from Merial on receipt of a Special Import Certificate (SIC) issued by the VMD to the named vet. The SIC is only required once but needs to accommodate all potential doses required, enabling Merial to supply to direct orders from the practice.
The product is available in 10 dose packs at a net price of £89.00 per pack.
For further information, contact Merial Customer Support Centre (UK) on 0870 6000 123 or your local equine territory manager.
The Land Rover Burghley Horse Trials has announced a £15,000 bursary to the Animal Health Trust. The bursary will be used to help fund the development of a rapid result blood test to identify horses infected with Strangles.
The AHT has already developed a test that can detect the disease, however the result is not known for 48 hours. The aim of the new research is to develop the test to produce a result within 10 minutes. The test, which is being developed in conjunction with Forsite Diagnostics Ltd, will be a useful tool for disease screening at sales and competitions.
"As an independent charity we receive no government funding and this bursary is extremely important to us and we are delighted to be working in partnership with The Land Rover Burghley Horse Trials on this specific project," said Dr Richard Newton of the AHT who is carrying out the research in partnership with Professor Andrew Waller. "Without this vital funding to carry out the painstaking work that will give us the confidence to launch the test, it will remain no more than a theoretical possibility."
The Bursary will be presented at this year's Land Rover Burghley Horse Trials (1- 4 September 2011) - in recognition of the 50th Anniversary of the event.
"With increasing horse movement, not only world-wide but closer to home between competitions and livery yards, preventing the spread of disease is an increasingly important challenge facing the horse world," said Elizabeth Inman Director of the Trials. "We are delighted to be able to play a part in this challenge and hope that this anniversary bursary will help to fast-track this new test out of the laboratory and into the field and thereby help reduce the spread of what is a horrible disease for horses and owners."
The webinar will take place at 11am and will be repeated at 7.30pm for those who are unable to listen during the day.
Hosted by Zoetis vet Dr Wendy Talbot the session will last for approximately an hour and equates to 8 AMTRA CPD points.
Wendy will explain the current situation and recommended approaches to help slow resistance.
The webinar will conclude with a live Q&A to give everyone the opportunity to discuss any queries, concerns or common questions they hear from their customers with Wendy.
Zoetis Equine Product Manager, Penny McCann said: "Our webinars continue to be very well received.
“This one is particularly important as it explains the important new thinking around the use of anthelmintics in order to address the serious challenge of resistance.
"It’s a must for all those involved with prescribing.”
To book the 11am webinar: https://register.gotowebinar.com/register/6163460189961597967 To book the 7.30pm webinar: https://register.gotowebinar.com/register/6394015684169009164
Equine obesity is a growing problem not just in the UK but around the world. The debate explored how various sectors of the equestrian industry see the challenges faced by people who are struggling to manage their horse’s weight. It included the views of equine vet Lucy Grieve, horse owner Helen Gale, livery yard owner and coach Beth Maloney, nutritionist Liz Bulbrook, competition judge David Ingle and equine welfare officer Penny Baker.
The session was chaired by equine vet and nutrition specialist Professor Pat Harris with the support of Dr Tamzin Furtado, a social scientist with a special interest in human behaviour change for animals.
The panellists shared their views on what they believed to be the blocks for horse owners in recognising obesity and addressing the problem.
They identified the importance of empowering owners and working with them to make step by step changes with the support of a reliable and trusted team including vet, nutritionist, yard owner and farrier.
Lucy said: “Vets are in unique and privileged position to provide an achievable and effective tailor-made strategy for individual horses.
"We must all learn to overcome avoidance and engage recognise, accept and understand, and tailor a solution.”
Helen added: “Owners need to be able to recognise and acknowledge that their horse has a weight problem and be motivated to take action. Communication is key. It’s important for others to understand why you are following the advice form vets and other experts and how they can best help."
There was recognition that a bespoke approach is needed for every horse, owner and situation. Some livery owners may face challenges in changing management practices and peer pressure on a yard may prevent people implementing intake restriction measures such as a grazing muzzle or restricted turnout.
Beth said: “Peer pressure can be daunting and there can be a lack of confidence that you are doing the right thing."
Communication and proactive signposting to reliable advice and scientific information were identified as pivotal, not only in helping to identify weight changes but also to build horse owners’ knowledge and confidence. This would build a clearer understanding of the calorific value of feeds and of grass and forage, what constitutes a balanced diet, the importance of regular exercise and weight monitoring, being able to identify the difference between fat and muscle and being familiar and comfortable with the range of weight control tactics, such as grazing muzzles, restricted grazing and track systems.
The language used was also identified as important; gauging the needs and response of the individual and asking the owner what they think, would be more effective than using potentially inflammatory language - for example choosing the phrase ‘fat pad’ rather than the terms ‘overweight’ or ‘obese’.
Lucy said: “If we are all being really honest with ourselves obesity is neglect. I doubt many vets would walk away from an emaciated horse or an infected wound or a cloudy eye so why are we so willing to walk away from these ticking time bombs which are actually a real welfare issue as the animal is potentially at risk of losing their life?”
You can buy tickets for a replay of the debate for £5, here: https://www.eventbrite.co.uk/e/the-great-weight-debate-equine-playback-tickets-138080533593
The 29th National Equine Forum will be held online on Thursday 4th March 2021. Tickets will be available in February 2021. If you'd like to be notified when they become available, you can subscribe here: https://www.nationalequineforum.com/subscribe/
Equistro® has produced a dust-free pelleted presentation of Secreta Pro, following requests from clients. Secreta Pro-Max® was launched to vets at BEVA Congress.
Secreta Pro is a respiratory supplement used to support the bronchial system and natural defences on a long term basis.
For more information on Secreta Pro-Max® and all Equistro products, please visit http://www.equistro.co.uk/, or contact your Vetoquinol representative.